Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
ID: 338829Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/338829

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)" aimed at supporting exploratory research for innovative technologies in biomedical research. This initiative encourages high-risk, high-reward projects that focus on developing broad-use technologies, such as laboratory instruments or algorithms, without established feasibility, thereby fostering advancements relevant to the missions of participating NIH Institutes, including the National Institute of General Medical Sciences, the National Institute on Aging, and the National Cancer Institute. Eligible applicants may receive up to $275,000 in direct costs over a two-year period, with applications evaluated based on significance, innovation, approach, and applicant expertise; however, projects that include proof of concept data will be deemed non-responsive. Interested parties should note that the application deadline is May 7, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-126.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is offering a funding opportunity (R21 - Clinical Trial Not Allowed) for exploratory research to develop innovative technologies in biomedical research. This initiative, focused on high-risk, high-reward studies, seeks projects that advance understanding and tools relevant to the missions of participating NIH Institutes, specifically the National Institute of General Medical Sciences (NIGMS), the National Institute on Aging (NIA), and the National Cancer Institute (NCI). Eligible applicants can propose projects that must not have established feasibility, focusing instead on developing broad-use technologies, such as laboratory instruments or algorithms, for various biomedical research applications. The funding amounts to a maximum of $275,000 in direct costs over two years, with specific submission deadlines and registration requirements highlighted. Applications will be evaluated based on significance, innovation, approach, and the expertise of the applicants. Notably, projects focusing on specific biological questions or that include any proof of concept data will be deemed non-responsive. This funding represents a strategic effort to foster early-stage technology development that facilitates biomedical advancements and innovation.
    Similar Opportunities
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting projects that develop innovative technologies to enhance biomedical research capabilities. Eligible applicants include a diverse range of institutions such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that have demonstrated proof of principle but still face significant technical challenges. This initiative emphasizes the development of laboratory instruments, algorithms, and biological systems, while applications targeting specific biomedical questions will not be funded. Interested parties should note that the application deadline is May 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-127.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21), aimed at supporting innovative early-stage research projects in the biomedical, behavioral, and clinical fields. This funding opportunity is specifically designed for basic experimental studies involving human participants, with a focus on developing novel techniques or methodologies that can significantly advance scientific understanding. Eligible applicants, including small businesses and various institutions, can receive funding of up to $275,000 over a two-year period, with applications accepted on a rolling basis until the close date of January 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PA-20-196.html.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 mechanism, aimed at fostering innovative engineering solutions to advance biomedical research. This funding opportunity encourages applications from a diverse range of organizations, including higher education institutions and nonprofits, to support exploratory projects that demonstrate feasibility and potential utility in addressing critical challenges in biomedical research and clinical care delivery, without involving clinical trials. The initiative emphasizes collaboration between quantitative and physical scientists and biomedical researchers, aiming to facilitate early-stage developments that can lead to significant advancements in medical technologies and methods. The funding ceiling is set at $275,000 over two years, with applications due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-090.html.
    Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)," aimed at supporting studies that address barriers to the adoption and sustainability of evidence-based health interventions, particularly in underserved communities. The initiative encourages research that promotes equitable access to effective practices and explores methods for discontinuing ineffective or harmful interventions, emphasizing the importance of contextual factors and multidisciplinary collaboration. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with a maximum funding amount of $275,000 and a project period of up to two years. Interested parties can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by May 7, 2025.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 funding mechanism, aimed at fostering innovative projects that address significant biomedical challenges. This funding opportunity encourages applications that explore new capabilities or improvements in biomedical research, clinical care delivery, and accessibility, with a focus on groundbreaking engineering research and collaboration across diverse scientific disciplines. Eligible applicants include higher education institutions, nonprofits, and small businesses, with a budget cap of $275,000 over two years, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-091.html.
    Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)" aimed at developing medical technologies that address health disparities among underserved populations in the U.S. This initiative encourages grant applications focused on creating effective, affordable, culturally acceptable, and accessible medical solutions, including devices, imaging systems, and telehealth innovations, while emphasizing the importance of formal collaborations with healthcare organizations serving these populations. The NIH plans to allocate approximately $2.4 million for this initiative, with an award ceiling of $500,000 per project, and expects to fund 3-4 awards over a project duration of up to four years. Interested applicants must submit their proposals by May 2, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.